Cannabis for Muscle Cramps

Plain-language summary

This is not medical advice. Talk to a clinician familiar with your condition before starting, stopping, or replacing any treatment.

'Muscle cramps' is a loose term covering several different problems with different evidence bases:

• Spasticity — chronic muscle stiffness from neurological damage (MS, spinal cord injury, stroke). This is what cannabis has actually been studied for.
• Spasms — sudden involuntary contractions, often painful, also common in MS and ALS.
• Ordinary cramps — the charley horse at 2 a.m., the calf cramp on a long run, period cramps. These are almost entirely unstudied with cannabis.

The strongest evidence is for nabiximols (Sativex), a standardized 1:1 THC:CBD oromucosal spray, in multiple sclerosis spasticity. Patients consistently report improvement; objective clinician-rated measures show smaller, less consistent effects ^[1][2]. For everything else, evidence ranges from weak to nonexistent.

What probably works (relatively speaking)

Nabiximols for MS spasticity. This is the best-studied use. Multiple randomized controlled trials and meta-analyses show that nabiximols modestly reduces patient-reported spasticity in people with MS who haven't responded adequately to first-line antispasticity drugs like baclofen or tizanidine Strong evidence^[1][2]. A 2017 National Academies report concluded there is substantial evidence that oral cannabinoids improve patient-reported MS spasticity symptoms ^[2]. Nabiximols is approved for this indication in the UK, Germany, Spain, Canada, and several other countries ^[3].

Important caveats:

• The effect size is modest. Roughly 30–40% of treated patients hit a clinically meaningful improvement, versus around 20% on placebo ^[1].
• Objective measures (Ashworth scale, physician assessment) often fail to show the same benefit as patient self-report Disputed^[2]. Whether this reflects real symptomatic improvement that objective scales miss, or a placebo/unblinding effect from THC's psychoactivity, is debated.
• The evidence is for the standardized 1:1 spray, not for arbitrary flower or edibles. Extrapolation to dispensary products is reasonable but not proven.

What might work

ALS-related cramps and spasticity. A small randomized trial of nabiximols in ALS (CANALS, 2019) found improvement in patient-reported spasticity compared to placebo Weak / limited^[4]. The trial was short and small; this is suggestive, not definitive.

Spinal cord injury spasticity. A handful of small trials of THC, nabilone, or nabiximols suggest possible benefit, but studies are underpowered and inconsistent Weak / limited^[2].

Dystonia. Case reports and small open-label studies suggest CBD or THC may reduce dystonic movements in some patients, but controlled trials are very limited and results are mixed Weak / limited^[5].

Parkinson's-related rigidity and dyskinesia. Mixed results across small trials. Some suggest benefit, others show no effect or worsening Disputed^[2].

In all of these, sample sizes are small, placebo effects are large, and blinding is hard because THC is psychoactive.

What doesn't have good evidence

Ordinary nocturnal leg cramps. No randomized controlled trials. The standard medical literature on nocturnal cramps doesn't mention cannabis as a treatment ^[6]. Plenty of people on cannabis forums say it helps; plenty of others say it doesn't. Anecdote

Exercise-associated muscle cramps. No trials. The leading hypothesis for these cramps is altered neuromuscular control (not dehydration or electrolytes, as commonly believed) ^[7]. There's no plausible reason cannabis would specifically address that, though it might reduce the perception of pain. No data

Menstrual cramps (dysmenorrhea). Survey data show many people use cannabis for period pain and report relief ^[8]. But there are no controlled trials demonstrating efficacy specifically for cramping versus general pain or mood effects. Anecdote

'Indica strains are best for cramps.' This is folklore. The indica/sativa labels don't reliably predict chemistry, let alone clinical effect Disputed^[9]. See Indica vs Sativa.

CBD alone for cramps. Despite heavy marketing, there is no good clinical evidence that CBD by itself relieves muscle cramps or spasticity at the doses sold in consumer products Weak / limited.

What we don't know

• Whether smoked or vaporized flower works as well as standardized oromucosal nabiximols for spasticity. Pharmacokinetics differ substantially, and trial data are thin.
• The right THC:CBD ratio for non-MS indications. The 1:1 ratio in nabiximols was a pragmatic choice, not the result of optimization.
• Whether long-term use causes tolerance to the antispasticity effect (it seems to, at least partially, but rigorous long-term data are limited).
• Whether topical cannabinoids do anything for localized cramps. Mechanistically, cramps originate in the central or peripheral nervous system, not the skin, so topical action is unlikely — but this hasn't been rigorously tested.
• Whether minor cannabinoids (CBG, THCV) or terpenes contribute meaningfully. Currently, no.

Comparison with standard treatments

For MS spasticity, first-line treatments are baclofen, tizanidine, gabapentin, and physical therapy. Nabiximols is positioned as add-on therapy when first-line drugs are inadequate or poorly tolerated ^[3]. It's not clearly superior to baclofen; it's an alternative when baclofen fails or causes too much weakness/sedation.

For nocturnal leg cramps, standard approaches are stretching, hydration, and review of medications that may cause cramps (statins, diuretics). Quinine works but is restricted in many countries due to cardiac and hematologic risks ^[6]. There is no comparative evidence for cannabis here.

For exercise cramps, the evidence-based approaches are conditioning, pacing, and possibly pickle juice or other strong oral stimuli that activate inhibitory neural reflexes ^[7]. Cannabis has no role in current sports medicine guidelines.

For menstrual cramps, NSAIDs (ibuprofen, naproxen) are first-line and well-supported. Hormonal contraception is second-line. Cannabis is, at best, an adjunct for symptom relief, not a substitute for evidence-based treatment.

Risks and trade-offs

• Psychoactive effects. THC causes intoxication, impaired driving, and in some users anxiety or paranoia. This is the main trade-off versus baclofen, which causes sedation and weakness but not a high.
• Tolerance and dependence. Daily THC use leads to tolerance and, in a meaningful minority, Cannabis Use Disorder.
• Drug interactions. CBD inhibits several cytochrome P450 enzymes and can raise levels of other drugs, including some antiepileptics and blood thinners ^[10].
• Falls and cognition. In older patients with neurological disease — exactly the population using cannabis for spasticity — THC increases fall risk and can worsen cognitive symptoms ^[2].
• Cardiovascular. Acute THC use raises heart rate and may transiently raise blood pressure; relevant for older patients with cardiac disease.
• Regulatory. Legal status varies enormously. Nabiximols is a prescription drug in many countries; dispensary cannabis is not, and quality control is uneven.

Again: this is not medical advice. If you have a neurological condition causing spasms or spasticity, work with a neurologist. If you have unexplained recurring cramps, get them evaluated — they can signal electrolyte problems, medication side effects, peripheral neuropathy, or other treatable conditions.

Sources

How this page was made

Related

• Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...